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Introduction
Osteoblasts are bone-specific, multifunctional cells that are re-
sponsible for bone formation through the synthesis of proteins 
of the bone extracellular matrix (Karsenty et al., 2009). Because 
osteoblasts express the osteoclast differentiation factor RANKL 
(receptor activator of nuclear factor –B ligand), they also favor 
bone resorption (Teitelbaum, 2000). In addition, osteoblasts are 
endocrine cells (Karsenty and Ferron, 2012). In agreement with 
the diversity of their functions, multiple extracellular cues can 
affect osteoblasts.
Parathyroid hormone (PTH) regulates Rankl expression 
through several mechanisms (Tawfeek et al., 2010). In one of 
them, PTH binds to its cognate receptor, PTH1R, a G protein–
coupled receptor on osteoblasts, and enhances Rankl expres-
sion in a cAMP-dependent manner (Kondo et al., 2002). Ex vivo 
assays have suggested that CREB mediates the PTH regulation 
of Rankl expression (Fu et al., 2002), but in vivo, however, inac-
tivation of Creb in osteoblasts does not affect Rankl expres-
sion or bone resorption. Thus, the transcriptional mechanisms 
whereby PTH signaling in osteoblasts affects Rankl expression 
are not elucidated (Kajimura et al., 2011). Another systemic cue 
affecting Rankl expression in osteoblasts is the sympathetic 
nervous system. Catecholamines, after their binding to another 
G protein–coupled receptor, the 2 adrenergic receptor, also use 
cAMP as a second messenger to enhance Rankl expression by 
recruiting the transcription factor ATF4 (Elefteriou et al., 2005). 
These observations raise the following question: How do two 
distinct regulatory signals that use the same second messenger 
elicit different transcriptional events in the same cell type?
Chromatin structure, which is influenced by posttransla-
tional modifications of histone proteins around which the DNA 
is wrapped, is a major determinant of gene expression (Jenuwein 
and Allis, 2001; Allis et al., 2007). Histone acetylation promotes 
gene transcription by relaxing the chromatin structure, whereas 
deacetylation of histones by histone deacetylases (HDACs) 
induces chromatin condensation and transcriptional repression 
(Berger, 2002; Verdin et al., 2003; Allis et al., 2007). Class II 
HDACs contain a poorly active catalytic domain and a long 
N-terminal extension to which transcription factors can bind. 
The existence of this domain has suggested that class II HDACs 
can link extracellular cues to the genome of a given cell (Verdin 
et al., 2003; Haberland et al., 2009).
One class II HDAC, HDAC4, prevents chondrocyte hy-
pertrophy in part by inhibiting the activity of the transcription 
factor Runx2, a master gene of skeletogenesis, in proliferating 
chondrocytes (Vega et al., 2004). Given the regulation of bone 
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the rest of this work, because of the cell-specific nature of the 
gene deletion, we studied Hdac4osb/ mice.
HDAC4 inhibits osteoclast  
differentiation by preventing MEF2c  
to transactivate Rankl
To elucidate how HDAC4 inhibits Rankl expression in osteo-
blasts, we asked whether members of the MEF2 family of tran-
scription factors regulate Rankl expression. There were two 
reasons to ask this question. The first one is the well-documented 
interaction of HDAC4 with MEF2 proteins in other cell types 
(Zhang et al., 2002). Second, there are three putative MEF2 
binding sites in the mouse Rankl promoter that are conserved in 
all vertebrate species analyzed, and Mef2a and Mef2c are highly 
expressed in osteoblasts (Fig. 2, A and B).
Chromatin immunoprecipitation assays verified that MEF2 
proteins could bind to each putative MEF2 binding site present 
in the mouse Rankl promoter (Fig. 2 C). In DNA cotransfection 
assays performed in COS cells, which do not express Rankl, 
an expression vector for Mef2c transactivated a construct con-
taining a 3-kb-long fragment of the Rankl promoter driving 
the luciferase gene (pRankl-luc); disrupting each of these three 
binding sites decreased the activity of this promoter fragment 
by ≥50% and abrogated MEF2c’s ability to activate pRankl-luc 
(Fig. 2 D). The results provided in vitro evidence suggesting 
that MEF2 proteins are important to regulate Rankl expression 
in osteoblasts.
To determine whether what was observed in vitro exists 
in vivo, we generated mutant mice lacking Mef2a or Mef2c in 
osteoblasts only and verified that this manipulation had efficiently 
deleted Mef2a or Mef2c from osteoblasts but not from other cell 
types (Fig. S2). Although mice lacking Mef2a in osteoblasts did 
not display any abnormalities of bone resorption, Mef2cosb/ 
mice exhibited a significant decrease in the bone surface covered 
by osteoclasts in all bones analyzed (Fig. 2 E). Serum CTX levels 
were also significantly lower in Mef2cosb/ than in Mef2cfl/fl mice, 
and Rankl expression was decreased nearly 50% in Mef2cosb/ 
compared with control mice (Fig. 2, F and G).
The opposite influence of HDAC4 and MEF2c on Rankl 
expression along with the ability of HDAC4 to interact physi-
cally with MEF2c suggested that HDAC4 might inhibit Rankl 
expression by hampering the transactivating function of 
MEF2c. Indeed, in DNA cotransfection experiments, the abil-
ity of MEF2c to transactivate the Rankl-luc construct in COS 
cells was abrogated when an Hdac4 expression vector was co-
transfected (Fig. 2 H). In vivo, Rankl expression, serum CTX 
values, and bone mass were normal in Hdac4osb/ mice lack-
ing one allele of Mef2c in osteoblasts only (Fig. 2, I–L). Col-
lectively, these results suggest the existence of an HDAC4  
MEF2c →Rankl regulatory loop in mouse osteoblasts regulat-
ing osteoclast differentiation.
PTH favors Rankl expression through 
MEF2c by promoting HDAC4  
proteasomal degradation
Next, we asked whether PTH signaling in osteoblasts promotes 
Rankl expression by disrupting this HDAC4  MEF2c →Rankl 
formation that Runx2 exerts through its expression in osteo-
blasts, this suggested that HDAC4 also regulates bone forma-
tion (Karsenty et al., 2009).
We show here that, in vivo, HDAC4 does not inhibit Runx2 
functions in osteoblasts but instead integrates PTH and sympa-
thetic signaling. PTH signaling in osteoblasts favors Rankl ex-
pression by inducing, via the E3 ubiquitin ligase Smurf2, HDAC4 
ubiquitination; this releases MEF2c, which can then activate Rankl 
expression. Conversely, the sympathetic tone promotes HDAC4 
accumulation in the nucleus of osteoblasts and its interaction with 
ATF4. Thus, under the control of the sympathetic tone, HDAC4 
favors Rankl and osteoclast differentiation. Lastly, HDAC4 does 
not inhibit Runx2 functions in osteoblasts in vivo because cate-
cholamines disrupt the physical interaction between HDAC4 
and Runx2. This study identifies HDAC4 as a link between two 
extracellular signals and the genome of osteoblasts.
Results and discussion
HDAC4 inhibits Rankl expression  
in osteoblasts
To study the functions of HDACs in osteoblasts, we asked which 
ones were expressed in these cells. Hdac5 expression was two-
fold higher in bone than in any other tissue (Fig. 1 B). Hdac4 
expression was also higher in bone than in other tissues where it 
exerts important functions (Fig. 1, A and B; Zhang et al., 2002; 
Chang et al., 2004; Vega et al., 2004). Similar results were ob-
tained at the protein level (Fig. 1 C).
We used Hdac5/ mice to study HDAC5 functions in os-
teoblasts and generated mice lacking Hdac4 in osteoblasts by 
crossing Hdac4fl/fl mice with mice expressing the Cre recombi-
nase under the control of Runx2 regulatory elements (Rauch 
et al., 2010). Before using Hdac4osb/ mice, because Runx2 ex-
pression is not restricted to osteoblasts, we verified that Hdac4 
had been efficiently deleted from osteoblasts but not from other 
cell types and that there was no overexpression of either Hdac4 
in the Hdac5/ mice or of Hdac5 in the Hdac4osb/ mice 
(Fig. S1, A and B).
Because HDAC4 inhibits Runx2 functions in chondrocytes, 
we expected that it would do the same in osteoblasts and that 
Hdac4osb
/ mice would display a high bone mass because of an 
increase in bone formation parameters. Instead, both Hdac4osb/ 
and Hdac5/ mice demonstrated a low bone mass phenotype 
affecting all bones tested. This was caused by a 50% increase in 
the bone surface covered by osteoclasts compared with control 
bones, whereas bone formation parameters were modestly affected 
(Fig. 1, D and E). This increase in bone resorption was caused by 
a marked increase in Rankl expression in Hdac4/ and Hdac5/ 
compared with control osteoblasts, whereas Opg expression was 
not changed to the same extent. As a result, the ratio of Rankl/
Opg was increased over 50% in Hdac4/ and Hdac5/ com-
pared with wild-type (WT) osteoblasts (Fig. 1, G–I). Expression 
of other regulatory genes and of type I collagen was normal in 
Hdac4/ osteoblasts (Fig. S1 C). Thus, through their expression 
in osteoblasts, HDAC4 and HDAC5 inhibit Rankl expression and 
bone resorption. An explanation for the absence of HDAC4’s 
influence on bone formation is proposed below (see Fig. 4 H). For 
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Figure 1. HDAC4 and HDAC5 inhibit Rankl expression in osteoblasts. (A) Expression of class IIa Hdacs in mouse osteoblasts. The expression of each gene 
is compared with the one of Hdac5. (B) Hdac4 (right) and Hdac5 (left) expression in various tissues. Expression of these genes in each tissue is compared 
with their expression in muscle. (C) HDAC4 and HDAC5 accumulation in different tissues. Anti-GAPDH was used as a loading control. (D and E) Histomor-
phometric analyses of vertebrae (D) and long bones (E) of Hdac4osb/ (n = 7) and Hdac5/ (n = 7) mice compared with Hdac4fl/fl (n = 8) or WT (n = 5) 
controls, respectively. BV/TV (%), percentage of bone volume over trabecular volume; NOsb/Bpm., number of osteoblasts per bone perimeter; BFR, bone 
formation rate; OcS/BS (%), percentage of osteoclast surface per bone surface. (F) Serum CTX levels in Hdac4fl/fl (n = 13), Hdac4 osb/ (n = 12), WT (n = 10), 
Hdac5/ (n = 9), and +/+Runx2-Cre (n = 4). Results are expressed as fold changes compared with levels seen in Hdac4fl/fl mice. (G) Rankl expression 
in Hdac4fl/fl (n = 4), Hdac4/ (n = 4; left), WT (n = 4), and Hdac5/ (n = 4; right) osteoblasts. (H and I) Opg expression (H) and Rankl/Opg ratio (I) in 
Hdac4fl/fl (n = 4), Hdac4/ (n = 4), WT (n = 4), and Hdac5/ (n = 4) osteoblasts. For G–I, results are expressed as fold changes compared with levels 
seen in Hdac4fl/fl or WT osteoblasts. Results are given as means ± SEM. *, P < 0.05 by Student’s t test. IB, immunoblot.
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Figure 2. HDAC4 prevents MEF2c to transactivate Rankl.(A) Putative MEF2 binding sites in the Rankl promoter of the mouse and other bony vertebrate 
species. Red letters indicate the core MEF2 binding sequence. (B) Mef2 gene expression in WT osteoblasts (n = 3). Expression of each gene is compared 
with the expression of Mef2a. (C) Chromatin immunoprecipitation assay in mouse osteoblasts analyzing MEF2 binding to the Rankl promoter. NTC, no 
template control. (D) DNA cotransfection assays in COS cells with a Rankl promoter luciferase construct (pRankl-luc) either WT or harboring a mutation in either 
one of the MEF2 binding sites alone or with a MEF2c expression vector. (E) Histomorphometric quantification the bone surface covered by osteoclasts and 
bone formation rate in vertebrae of Mef2afl/fl (n = 5), Mef2aosb/ (n = 5), Mef2cfl/fl (n = 6), and Mef2cosb/ (n = 8; left) mice and long bones of 
Mef2cfl/fl (n = 6) and Mef2cosb/ (n = 8) mice (right). BFR, bone formation rate; OcS/BS (%), percentage of osteoclast surface per bone surface. (F) Serum 
CTX levels in Mef2afl/fl (n = 8), Mef2aosb/ (n = 7), Mef2cfl/fl (n = 6), and Mef2cosb/ (n = 7) mice. Results are represented as fold changes compared with 
levels seen in Mef2cfl/fl mice. (G) Rankl expression in Mef2afl/fl (n = 8), Mef2aosb/ (n = 7), Mef2cfl/fl (n = 13), and Mef2cosb/ (n = 14) mice. Results are 
expressed as fold changes compared with levels seen in Mef2cfl/fl mice. (H) DNA cotransfection assays in COS cells of pRankl-luc either WT or mutant for 
the MEF2 binding site 1, along with MEF2c and HDAC4 expression vectors. (I) Histomorphometric quantification of the bone surface covered by osteoclasts 
in the vertebrae of control (n = 5), Mef2cosb+/ (n = 4), Hdac4osb/ (n = 4), and Hdac4osb/;Mef2cosb+/ (n = 3) mice. (J) Rankl expression in control (n = 10), 
Mef2cosb+/ (n = 4), Hdac4osb/ (n = 4), and Hdac4osb/;Mef2cosb+/ (n = 5) calvaria. (K) Serum CTX levels of control (n = 6), Mef2cosb+/ (n = 3), 
Hdac4osb/ (n = 4), and Hdac4osb/;Mef2cosb+/ (n = 3) mice. In I and K, results are presented as fold changes compared with levels seen in control mice. 
(L) Histomorphometric analyses of BV/TV percentage in vertebrae of control (n = 9), Mef2cosb+/ (n = 4), Hdac4osb/ (n = 5), and Hdac4osb/;Mef2cosb+/ 
(n = 3) mice. Results are given as means ± SEM. *, P < 0.05 by Student’s t test.
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Figure 3. PTH favors Rankl expression by disrupting the HDAC4–MEF2c interaction. (A) DNA transfection assays in ROS17/2.8 cells using a pRankl-luc 
reporter construct for either WT (pRankl-luc) or mutated for each MEF2 binding site. Cells were treated with PTH or vehicle for 16 h. (B) Western blot 
analysis of total extracts from primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti–-actin antibodies. 
(C) Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. 
(D) Immunofluorescence assays showing MEF2c localization in mouse primary osteoblasts treated with vehicle or PTH. (E) Immunofluorescence assays showing 
HDAC4 localization in mouse primary osteoblasts treated with vehicle, PTH, or PTHrP. (F) Immunoprecipitation of HDAC4 in WT primary osteoblasts treated 
with vehicle or PTH plus bortezomib. Proteins were analyzed by Western blotting using anti-HDAC4 or anti-HDAC4 phospho-S246 antibodies. (G) Rankl 
expression in primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib. Results are presented as fold changes compared with levels seen in ve-
hicle-treated osteoblasts. (H) Immunoprecipitation of HDAC4 in primary osteoblasts treated with vehicle or PTH plus bortezomib. Proteins were analyzed by 
Western blotting using anti-HDAC4 or antiubiquitin antibodies. (I) Analysis of expression of E3 ubiquitin ligases in WT primary osteoblasts treated with PTH. 
Results for each gene are presented as fold change compared with levels seen in vehicle-treated osteoblasts. (J) Rankl expression in scrambled-, Synv1-, or 
Smurf2 siRNA–transfected primary osteoblasts. Results are represented as fold changes compared with levels seen in scrambled siRNA–transfected cells. 
(K) Rankl expression in scrambled-, Smurf2-, or Synv1 siRNA–transfected primary osteoblasts treated with vehicle or PTH. Results are presented as fold changes 
compared with levels seen in vehicle-treated scrambled siRNA–transfected cells. (L) Coimmunoprecipitation assay in ROS17/2.8 cells showing interaction 
between FLAG-Smurf2 and HA-HDAC4. Cytoplasmic extracts (CE) were immunoprecipitated after treatment with PTH or vehicle with an anti-FLAG antibody, 
and proteins were detected by Western blotting with anti-HA or anti-FLAG antibodies. (M) Analysis of Rankl expression in WT or Ppr+/;Smurf2+/ primary 
osteoblasts treated with vehicle or PTH. (N) Western blot analysis of total extracts from primary osteoblasts treated with vehicle or PTH using anti-HDAC4 
and anti–-actin antibodies. Results are given as means ± SEM. *, P < 0.05 by Student’s t test. IB, immunoblot; IP, immunoprecipitation.
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by inducing its dephosphorylation on S246 (Kozhemyakina et al., 
2009). PTH induced the same dephosphorylation in HDAC4 in 
mouse osteoblasts (Fig. 3 F), but this could not explain our find-
ings, as PTH induces a near complete disappearance of HDAC4 
from osteoblast nuclei (Fig. 3 C).
Because PTH does not decrease Hdac4 expression in os-
teoblasts (Fig. S3 A), we asked whether it induces proteasomal 
degradation of HDAC4 in osteoblasts. In support of this idea, 
the PTH-induced decrease of HDAC4 accumulation in osteoblasts 
was prevented by the addition of an inhibitor of proteasomal 
pathway. PTH increased the activity of pRankl-luc in ROS17/2.8 
osteoblastic cells, and mutating the first MEF2 binding site in 
this promoter abrogated this effect of PTH (Fig. 3 A). Addition-
ally, PTH triggered a marked decrease in HDAC4 accumulation 
in both the cytoplasm and the nucleus of mouse osteoblasts, with-
out affecting MEF2c accumulation. This is different from what is 
observed after treatment of osteoblasts with PTH-related pro-
tein (PTHrP), a molecule that bears similarities to PTH and that 
signals through the same receptor (Fig. 3, B–E; Kronenberg, 
2003), because PTHrP allows HDAC4 to move to the nucleus 
Figure 4. The sympathetic tone stabilizes HDAC4 to favor Rankl expression. (A) Expression of Hdac4 and in primary osteoblasts treated with vehicle or 
ISO for 2 h. Results are presented as fold changes compared with levels seen in vehicle-treated cells. (B) Immunofluorescence detection of HDAC4 in WT 
primary osteoblasts treated with vehicle or ISO. (C) Coimmunoprecipitation assay in ROS17/2.8 cells showing an interaction between FLAG-ATF4 and 
HA-HDAC4. Nuclear extracts (NE) were immunoprecipitated after ISO treatment with an anti-FLAG antibody, and proteins were detected by Western blot-
ting with anti-HA or anti-FLAG antibodies. The numbers shown under each lane of the top blot represent the fold enhancement in intensity of the bands. 
(D) Immunoprecipitation of HDAC4 in mouse primary osteoblasts treated with vehicle or ISO. Proteins were analyzed by Western blot using anti-HDAC4 
or anti–HDAC4-S246P antibodies. (E) Serum CTX levels in control (n = 8), Hdac4osb+/ (n = 3), Atf4osb+/ (n = 3), and Atf4osb+/; Hdac4osb+/ (n = 3) mice, 
shown as fold changes compared with control levels. (F) Rankl expression in long bones of control (n = 8), Hdac4osb+/ (n = 3), Atf4osb+/ (n = 3), and 
Atf4osb+/;Hdac4osb+/ (n = 3) mice. Results are presented as fold changes compared with levels seen in WT bones. (G) Histomorphometric quantifica-
tion of the bone surface covered by osteoclasts in vertebrae of control (n = 8), Hdac4osb+/ (n = 3), Atf4osb+/ (n = 3), and Atf4osb+/;Hdac4osb+/ (n = 3) 
mice. OcS/BS (%), percentage of osteoclast surface per bone surface. (H, left) Coimmunoprecipitation assay in ISO-treated ROS17/2.8 cells showing 
interaction between FLAG-Runx2 and HA-HDAC4. Nuclear extracts were immunoprecipitated with the anti-FLAG antibody. Purified proteins were detected 
by Western blotting with anti-HA or anti-FLAG antibodies. (right) Immunoprecipitation of Runx2 in mouse osteoblasts treated with vehicle or ISO. Proteins 
were analyzed by Western blotting using an anti-Runx2 or anti-HDAC4 antibodies. Results are given as means ± SEM. *, P < 0.05 by Student’s t test. IB, 
immunoblot; IP, immunoprecipitation.
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(Fig. 4 A), but unlike PTH, ISO increased HDAC4 accumu-
lation in the nucleus of osteoblasts and promoted its interaction 
with ATF4 (Fig. 4, B and C). ISO also decreased the phosphory-
lation of HDAC4 on S246, an event that favors HDAC4 translo-
cation to the nucleus (Fig. 4 D). In vivo, mice lacking one allele 
of Hdac4 and one allele of Atf4 only in osteoblasts demonstrated 
a significant decrease in Rankl expression, circulating CTX val-
ues, and the bone surface covered by osteoclasts (Fig. 4, E–G). 
Of note, although ISO treatment of ROS17/2.8 osteoblastic cells 
or mouse osteoblasts increased the interaction between HDAC4 
and ATF4, it disrupted in tandem the interaction between HDAC4 
and Runx2. This latter observation provides an explanation as to 
why in the living animal, in which sympathetic signaling is con-
stantly present, disruption of HDAC4 in osteoblasts does not 
affect Runx2-regulated bone formation (Ducy et al., 1999).
This study reveals that Hdac4, through its expression in 
osteoblasts, prevents expression of Rankl, the major osteoclast 
differentiation factor, and serves as a bridge between two extra-
cellular cues, regulating Rankl expression and the genome of 
osteoblasts (Fig. 5). On the one hand, PTH signaling in osteo-
blasts favors Rankl expression by inhibiting HDAC4 functions. 
To do that, PTH induces the ubiquitination of HDAC4 by en-
hancing the expression of an E3 ubiquitin ligase, Smurf2, in os-
teoblasts and promoting the interaction of Smurf2 and HDAC4. 
This frees MEF2c that can transactivate the Rankl promoter. 
Our results do not exclude in any way the fact that PTH also fa-
vors Rankl expression in osteoblasts by signaling in T lympho-
cytes (Gao et al., 2008; Tawfeek et al., 2010). On the other hand, 
the sympathetic tone favors the accumulation of HDAC4 in 
osteoblasts and its interaction with ATF4, the only known tran-
scriptional mediator of the sympathetic regulation of Rankl 
expression (Elefteriou et al., 2005). This mechanism is different 
from the PKA-induced proteolysis described by Backs et al. 
(2011) in cardiomyocytes. Although we cannot exclude that such 
a proteolysis occurs in osteoblasts, we note that if it were the 
case, ISO would prevent the expression of Rankl instead of 
increasing it.
degradation, bortezomib (Fig. 3, B and C). Bortezomib also sig-
nificantly decreased the ability of PTH to up-regulate Rankl ex-
pression in osteoblasts, and treating osteoblasts with PTH and 
bortezomib induced ubiquitination of HDAC4 (Fig. 3, G and H).
PTH up-regulated the expression of two E3 ubiquitin li-
gases that are highly expressed in osteoblasts Smurf2 and Synv1 
(Fig. 3 I; Sévère et al., 2013). We tested whether Smurf2 and 
Synv1 are involved in PTH signaling in osteoblasts through siRNA 
knockdown experiments. In each experiment, we verified that we 
had efficiently decreased either Smurf2 or Synv1 accumulation, 
while not affecting Hdac4 expression (Fig. S3, B and C). Decreas-
ing Synv1 accumulation in osteoblasts increased Rankl expres-
sion and did not prevent PTH from inducing Rankl expression, 
whereas decreasing Smurf2 accumulation in mouse osteoblasts 
significantly lowered the expression of Rankl and hampered 
the ability of PTH to induce Rankl expression (Fig. 3, J and K). 
Three additional experimental evidences suggested that Smurf2 is 
a major target of PTH signaling in osteoblasts: first, Smurf2 in-
teracts with HDAC4 only in the presence of PTH; second, PTH 
did not trigger HDAC4 ubiquitination in Smurf2/ osteoblasts; 
and third, the PTH induction of Rankl expression was decreased 
nearly 50% in osteoblasts lacking one allele of Ppr (encoding 
the PTH receptor) and one allele of Smurf2 (Fig. 3, J–N). These 
results indicate that PTH favors Rankl expression in osteoblasts, 
in part, by recruiting Smurf2 to ubiquitinate HDAC4. This ab-
rogates the physical interaction between HDAC4 and MEF2c 
and allows MEF2c to activate the Rankl promoter.
The sympathetic tone favors Rankl 
expression by stabilizing HDAC4
That PTH regulates Rankl expression in an HDAC4-dependent 
manner raised the hypothesis that another systemic regulator of 
Rankl expression in osteoblasts, the sympathetic nervous sys-
tem (Elefteriou et al., 2005), might also recruit HDAC4 to 
achieve this function. To test whether this was the case, we 
treated mouse osteoblasts with isoproterenol (ISO), a surrogate of 
the sympathetic tone. Like PTH, ISO favored Hdac4 expression 
Figure 5. Model of HDAC4 functions in os-
teoblasts. PTH signaling favors HDAC4 (in 
gray) degradation through ubiquitination; this 
releases MEF2c, which can transactivate the 
Rankl promoter and favor bone resorption. The 
sympathetic tone favors HDAC4 accumulation, 
its translocation to the nucleus, its association 
with ATF4, and thereby, Rankl expression. The 
broken lines indicate that additional proteins 
yet to be identified are involved.
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type 2 (Worthington Biochemical Corporation) and 0.25% trypsin-EDTA 
(Life Technologies). Cells of the first digest were discarded, whereas cells 
released from the second digestion were plated in -MEM and 10% fetal 
bovine serum. For in vitro gene inactivation, floxed osteoblasts were di-
vided into two groups and infected with either GFP- or Cre-expressing ade-
novirus (University of Iowa). For siRNA transfections, osteoblasts were 
transfected with siRNA pools (On-TARGETplus; Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. For immunofluorescence, cells 
were trypsinized, replated after 2 d of culture, and left in regular media con-
ditions for 1 d. On experiment day, cells were washed twice with PBS and 
treated with indicated amounts of PTH (1–34) (10 nM; ProSpec), PTHrP 
(1–36) (10 nM; Bachem), ISO (10 µM; Sigma-Aldrich), and bortezomib 
(25 nM; Selleckchem) for 2 h. Immunofluorescence was performed using a 
standard protocol. Pictures were obtained on a confocal microscope (LSM 
710; Carl Zeiss) at 63× magnification. For gene expression, osteoblasts 
were cultured in -MEM containing 10% FBS supplemented with 5 mM 
-glycerophosphate and 100 µg/ml ascorbic acid for 10 d. Cells were 
fasted in serum-free media for 16 h and treated with 10 nM PTH, 10 µM 
ISO, or 25 nM bortezomib for 2 h. Cells were then collected in TRIZOL (Invit-
rogen), and RNA isolation, cDNA preparation, and real-time PCR analysis 
were performed following standard protocols. In brief, total RNA was ex-
tracted, DNase I treated, and reverse transcribed with random primers using 
the cDNA synthesis kit (SuperScript III; Invitrogen). The cDNA samples were 
then used as templates for quantitative PCR analysis that was performed 
using the Taq SYBR Green Supermix with ROX (Bio-Rad Laboratories) and 
specific primers (Table S1) on a CFX Connect apparatus (Bio-Rad Labora-
tories). Expression levels of all quantitative PCR reactions were normalized 
using hprt expression levels as an internal control for each sample.
Molecular biology and biochemistry
For DNA cotransfection assays, COS cells were cultured in DMEM sup-
plemented with 10% FBS. Cells were transfected with 100 ng pCMV14-
FLAG-MEF2c or 10 ng pCDNA3.1-HA-HDAC4 expression vectors, 
pGL3-Basic-Rankl (pRankl-luc), pGL3-Basic-Rankls1 (pRankls1-luc), pGL3-
Basic-Rankls2 (pRankls2-luc), or pGL3-Basic-Rankls3 (pRankls3-luc; 5 ng), 
and pCMV–-gal reporter vectors. DNA transfections were performed in 
ROS17/2.8 cells cultured in DMEM F12 (1:1) supplemented with 10% 
FBS. Cells were transfected with 5 ng pRankl-luc or 5 ng pRankls1-luc and 
200 ng pCMV–-gal reporter vectors. 32 h after transfection, cells were 
washed with PBS and treated with serum-free media containing either 
10 nM PTH or vehicle for the indicated times. Luciferase and -gal assays 
were performed using standard procedures. For coimmunoprecipitation 
assays, ROS17/2.8 cells were transfected with 6 µg pCMV5-FLAG-ATF4, 
6 µg pCMV5-FLAG-Runx2, 6 µg pCMV5-Smurf2, or pCDNA3.1-HA-
HDAC4 (2 µg). 48 h later, cells were washed with PBS and treated with 
media containing 0.1% FBS and 10 nM PTH, 25 nM bortezomib, or 
10 µM ISO for 2 h. Cells were lysed in hypotonic buffer and disrupted by 
Dounce homogenizer. The cytosolic fraction was separated from the pellet 
by centrifugation at 4°C. The nuclear-soluble fraction was obtained by in-
cubation of the pellet in high-salt buffer to get a final NaCl concentration 
of 300 mM. Tagged proteins from each fraction were immunoprecipitated 
with anti-Flag M2 overnight. The next day, protein G–agarose beads were 
added and incubated for 2 h at 4°C. Each immunoprecipitation was 
washed five times with TGEN 150 buffer (20 mM Tris, pH 7.65, 150 mM 
NaCl, 3 mM MgCl2, 0.1 mM EDTA, 10% glycerol, and 0.01% NP-40), 
and proteins were eluted with Laemmli buffer and boiled for 10 min. For 
immunoprecipitation in primary osteoblasts, cells were lysed with 20 mM 
Tris, pH 7.65, 150 mM NaCl, and 1% NP-40 in and disrupted by Dounce 
homogenizer. The soluble fraction was incubated with indicated antibod-
ies overnight at 4°C. The next day, protein G–agarose beads were added 
and incubated for 2 h at 4°C. Each immunoprecipitation was washed five 
times with TGEN 150 buffer (20 mM Tris, pH 7.65, 150 mM NaCl, 3 mM 
MgCl2, 0.1 mM EDTA, 10% glycerol, and 0.01% NP-40), and proteins 
were eluted with Laemmli buffer and boiled for 10 min.
Antibodies used in this study are mouse monoclonal anti-FLAG 
(F3165; Sigma-Aldrich), rabbit polyclonal anti-MEF2c (ab79436; Abcam), 
rabbit polyclonal anti-MEF2 (sc-313X; Santa Cruz Biotechnology, Inc.), rabbit 
polyclonal anti-HDAC4 (sc-11418; Santa Cruz Biotechnology, Inc.), rabbit 
monoclonal anti-HA (C29F4; Cell Signaling Technology), rabbit polyclonal 
anti-HDAC5 (2082; Cell Signaling Technology), rabbit polyclonal anti–
phospho-HDAC4S-246 (provided by T.P. Yao, Duke University School of 
Medicine, Durham, NC; Cohen et al., 2007), rabbit monoclonal anti-GAPDH 
(14C10; Cell Signaling Technology), and mouse monoclonal antiubiquitin 
(3936; Cell Signaling Technology). DAPI was included in the mounting media 
(Electron Microscopy Sciences).
Lastly, that compound heterozygous mice lacking one 
allele of Ppr in osteoblasts and one allele of Mef2c also in 
osteoblasts have normal bone resorption parameters (unpub-
lished data) argues against the existence of a cross talk between 
the two arrows of the current models. The different mecha-
nisms whereby PTH and the sympathetic tone use HDAC4 as 
an intermediary step to fulfill their functions in osteoblasts 
suggest that these two extracellular cues must recruit different 
intracellular signaling molecules. Further biochemical studies 
will help clarify this aspect of PTH and sympathetic signaling 
in osteoblasts.
Materials and methods
Mouse generation
As previously reported, Hdac5/ mice were generated by fusing in frame 
the lacZ cDNA and neomycin resistance cassette under the control of the 
phosphoglycerate kinase promoter to the 5 region of exon 3, therefore plac-
ing a -galactosidase (-gal) reporter gene under the control of endoge-
nous Hdac5 promoter (provided by E. Olson and R. Bassel-Duby, University 
of Texas Southwestern Medical Center, Dallas, TX; Chang et al., 2004). 
Hdac4 floxed mice were generated by the insertion of loxP sites, flanking 
exon 6, which results in an out-of-frame mutation in the Hdac4 allele (pro-
vided by E. Olson and R. Bassel-Duby; Potthoff et al., 2007). Hdac4osb/ 
mice were generated by intercrossing Hdac4fl/fl mice with Runx2-Cre trans-
genic mice (Rauch et al., 2010). Mef2a and Mef2c conditional alleles 
were generated by flanking exon 2 with loxP sites of each gene (provided 
by E. Olson and R. Bassel-Duby; Arnold et al., 2007; Akhtar et al., 2012). 
Mef2aosb/ and Mef2cosb/ mice (C57BL/6J) were generated by inter-
crossing Mef2afl/fl or Mef2cfl/fl mice and Runx2-Cre transgenic mice. 
Hdac4osb/;Mef2cosb+/ mice were obtained from crosses between F2 
generation Hdac4osb+/;Mef2cosb+/ and Hdac4fl/fl or Hdac4osb+/ and 
Hdac4osb+/;Mef2cosb+/ mice. The Atf4 conditional allele was generated 
by placing a floxed neomycin cassette upstream of exon 2 and a loxP site 
downstream of exon 3 (Yoshizawa et al., 2009). Hdac4osb+/;Atf4osb+/ mice 
were generated by crossing Atf4fl/fl or Atf4fl/+ mice with Hdac4osb+/ mice. 
Hdac4fl/fl, Mef2afl/fl, or Mef2cfl/fl mice littermates were used for the control 
mice for Hdac4osb/, Mef2aosb/, and Mef2cosb/ mice, respectively. 
Floxed mice and Cre-expressing mice littermates (control in the figures) were 
used as control mice for Hdac4osb/;Mef2cosb+/ and Hdac4osb+/;Atf4osb+/. 
Pprfl/fl mice were provided by H. Kronenberg (Massachusetts General Hos-
pital, Boston, MA). Mice genotypes were determined by PCR. All animal 
procedures were approved by the Columbia University Medical Center 
Institutional Animal Care and Use Committee and conform to the relevant 
regulatory standards.
Bone histomorphometry
Lumbar vertebrae or tibia dissected from 2- or 3-mo-old male mice were fixed 
for 24 h, dehydrated with graded concentrations of ethanol, and embedded 
in methyl methacrylate resin according to standard protocols. Von Kossa/
Van Gieson, toluidine blue, and tartrate-resistant acid phosphatase stainings 
were used to measure bone volume over tissue volume (BV/TV) and osteo-
blast and osteoclast numbers and surface, respectively. Bone formation rates 
were assessed after calcein double labeling. Calcein (Sigma-Aldrich) was 
dissolved in calcein buffer (0.15 M NaCl and 2% NaHCO3) and injected 
twice at 0.125 mg/g body weight on days 1 and 4, and mice were killed 
on day 6. Vertebrate pictures for Von Kossa/Van Gieson were obtained 
using a microscope (DM4000B; Leica) equipped with a camera (DFC300 
FX; Leica) using a 2.5× magnification. Images were acquired with Fire soft-
ware (Leica), and BV/TV was analyzed using ImageJ software (National 
Institutes of Health). All quantifications were acquired with a fluorescent 
microscope (DMLB; Leica) equipped with a charge-coupled device camera 
(DXC-390; Sony) at 40× magnification. Analysis of the parameters was per-
formed using OsteoMeasure Analysis system (OsteoMetrics).
Cell-based assays
Primary osteoblasts were isolated from calvaria of 2-d-old mice as de-
scribed previously (Ducy and Karsenty, 1995; Ferron et al., 2010). In 
brief, calvaria were sequentially digested for 5 and 60 min at 37°C in 
-modified MEM (-MEM; Life Technologies) containing 1 mg/ml collagenase 
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Chromatin immunoprecipitation
Mouse osteoblasts were washed twice with PBS and cross-linked with 1.1% 
formaldehyde for 10 min at 37°C. Cross-linking was stopped by 125 mM 
glycine with gentle rocking. Cells were washed with PBS containing 0.25 
mM PMSF, nuclear extracts were prepared, and each sample was soni-
cated to obtain sheared fragments of 200–800 bp. Samples were pre-
cleared with normal rabbit IgG with incubation for 1 h and agarose 
G beads for 2 h at 4°C. An anti-MEF2 antibody was added to cleared ly-
sates and incubated overnight at 4°C. The next day, agarose protein G 
beads were blocked with 200 µg/ml salmon sperm DNA and 1 mg/ml 
BSA for 1 h at 4°C. Lysates were incubated with blocked beads for 2 h at 
4°C and washed once in low salt buffer, twice in high salt, twice in LiCl 
buffer, and twice in Tris EDTA buffer. Washed beads were eluted in elution 
buffer by incubating at 37°C for 2 h. The DNA was reverse cross-linked by 
incubating all samples at 65°C for 6 h. After DNA extraction, PCR analysis 
was performed on chromatin immunoprecipitated material with specific 
primers (for binding sites 1 and 2, 5-GGGTCCTCTTAGCACCTTGAC-3 and 
5-GACATGCTTAGATGAAAAATG-3; for binding site 2, 5-GTGGCAT-
GGGTTTATTTATT-3 and 5-TCCTGAGTGCTGGGATTAAA-3; for binding 
site 3, 5-AGGCTCTCTTGTGACCTAGAG-3 and 5-CACACTTCCCACTTT-
GCCCAC-3; for 3UTR, 5-CTAGAATTTCCCCAAGTCTTC-3 and 5-GGC-
TGGCCCCTATCCTTTGC-3) designed to detect the Mef2 binding sites within 
the mouse Rankl promoter.
Statistical analyses
Results are given as means ± SEM. Statistical analyses were performed 
using unpaired, two-tailed Student’s t test. In all figures, error bars repre-
sent SEM, and asterisks represent P < 0.05.
Online supplemental material
Fig. S1 shows osteoblast-specific deletion of Hdac4. Fig. S2 shows osteoblast-
specific deletion of Mef2a and Mef2c. Fig. S3 shows that PTH regulation of 
Hdac4 expression is independent of Smurf2 or Synv1 inactivation. Table 
S1 shows primers used in this study. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201403138/DC1.
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